Climb Bio Company Leadership
| CLYM Stock | 1.95 0.08 3.94% |
Climb Bio employs about 9 people. The company is managed by 5 executives with a total tenure of roughly 21 years, averaging almost 4.0 years of service per executive, having 1.8 employees per reported executive. Analysis of Climb Bio's management performance can provide insight into the firm performance.
Climb |
Climb Bio Workforce Comparison
Climb Bio is rated second in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 35.0. Climb Bio totals roughly 9.0 in number of employees claiming about 26% of stocks in Biotechnology industry.
Climb Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Climb Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Climb Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Climb Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Emily Pimblett 3 days ago Acquisition by Emily Pimblett of 5000 shares of Climb Bio subject to Rule 16b-3 | ||
Williams Douglas E over a month ago Insider Trading |
Climb Bio Notable Stakeholders
A Climb Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Climb Bio often face trade-offs trying to please all of them. Climb Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Climb Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| BAO BCh | President CEO | Profile | |
| MD MBA | COO Officer | Profile | |
| Jo PalmerPhillips | Chief Officer | Profile | |
| Emily Pimblett | Chief Officer | Profile | |
| Nishi MD | Senior Development | Profile |
About Climb Bio Management Performance
The success or failure of an entity such as Climb Bio often depends on how effective the management is. Climb Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Climb management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Climb management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Climb Bio is entity of United States. It is traded as Stock on NASDAQ exchange.
Climb Bio Workforce Analysis
Traditionally, organizations such as Climb Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Climb Bio within its industry.Climb Bio Manpower Efficiency
Return on Climb Bio Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3.9M | |
| Net Loss Per Executive | 7M | |
| Working Capital Per Employee | 11.9M | |
| Working Capital Per Executive | 21.5M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.